EN DE

Raily Aesthetic Medicine Intl Hldg (2135) Fair Value & Analysis

Healthcare · HK · Market cap HK$68.5M (≈ $8.7M) · ISIN KYG7356A1058

What is Raily Aesthetic Medicine Intl Hldg really worth?

RA Raily Aesthetic Medicine Intl Hldg 2135 · HK
PriceHK$0.1160
Fair ValueHK$0.0680
Upside−41.4%
Quality53/100

A solid business, but trading 71% above our fair value of HK$0.0680.

As of Aug 13, 2026, the fair value of Raily Aesthetic Medicine Intl Hldg is HK$0.0680 per share against a price of HK$0.1160, so the fair value sits 41% below the price. A model estimate blended from multiple valuation models, recalculated regularly.

Watch Raily Aesthetic Medicine Intl Hldg for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free

Strengths

✓Low debt · generates free cash flow

Risks

!Mixed Growth (revenue 5y +2.3 %/yr)
!Thin margins · 1.0% net margin
!Mixed vs. peers (6/11)
!Narrow moat 23/100
!Evidence only low, so the estimate is less certain
Evidence: Low Range HK$0.0510 – HK$0.0850

Fair value as of: Aug 13, 2026

From 25 valuation models · updated 23 days ago

Share price +20.8% over the past month.

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

What matters now

  • The price sits above even our optimistic bull case (HK$0.0850). The favourable scenario is already priced in.
  • The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
  • Solid but not exceptional quality (53/100) and above fair value, neither a clear bargain nor a standout compounder.

Price vs Fair Value (5 years)

HK$4.00 HK$0.0591 Fair Value HK$0.0680 Mar 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.

How to read this chart

60‑month range HK$0.0591 – HK$4.00 · fair‑value band HK$0.0510 – HK$0.0850 · the HK$0.1160 price screens above the HK$0.0680 fair value. Dashed = 300-day average. As of Aug 13, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Raily Aesthetic Medicine Intl Hldg (2135) currently trades at HK$0.1160, while our model-based Fair Value estimate is HK$0.0680, implying the stock looks roughly 70.6% overvalued today. The Quality Score stands at 53/100 (solid quality), in the Healthcare sector. Bull case: the DCF Models group reads highest at a median of HK$0.4800 per share, and 18 of the 25 models we run sit above the HK$0.1160 price. Bear case: the Earnings-Based group reads lowest at HK$0.0500, and 7 of the 25 models stay below the price. Evidence for this calculation is low.

Over the trailing twelve months, Raily Aesthetic Medicine Intl Hldg generated revenue of HK$189M at a net margin of 1.0%. Revenue grew 28.0% year over year. It earns a return on equity of −2.3%. Net debt stands at HK$1.4M. Fundamentals as of Aug 13, 2026

Our scenario range runs from HK$0.0510 (bear case) to HK$0.0850 (bull case); at HK$0.1160, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 41% below its 52-week high and 10% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −41%, 2135 screens richer than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted, family-balanced blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small. Every input is real reported data, nothing guessed.

Model Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence
Highest evidence
FCF DCF best evidence HK$0.5500 HK$0.6800 HK$0.8200 82
Growth DCF HK$0.5600 HK$0.6700 HK$0.8000 80
Owner Earnings HK$0.4000 HK$0.4800 HK$0.5700 78
All 25 models by family
DCF Models
FCF DCF best evidence HK$0.5500 HK$0.6800 HK$0.8200 82
Owner Earnings HK$0.4000 HK$0.4800 HK$0.5700 78
5Y Revenue Exit HK$0.3500 HK$0.4000 HK$0.4500 74
5Y EBITDA Exit HK$0.5500 HK$0.7400 HK$0.9600 76
5Y P/E Exit HK$0.3300 HK$0.3700 HK$0.4000 72
10Y Revenue Exit HK$0.4400 HK$0.4900 HK$0.5500 68
10Y EBITDA Exit HK$0.5400 HK$0.6900 HK$0.8600 70
10Y P/E Exit HK$0.4300 HK$0.4800 HK$0.5200 65
Earnings-Based
Graham-Dodd HK$0.0200 HK$0.0500 HK$0.0600 66
PEG = 1.0 HK$0.0100 HK$0.0100 HK$0.0100 57
EPV HK$0.1400 HK$0.1500 HK$0.1500 74
Dividend Discount
Gordon GGM HK$0.2300 HK$0.3300 HK$0.4100 69
DDM Multi-Stage HK$0.2300 HK$0.3100 HK$0.3800 67
Multiples
P/E Multiple HK$0.0500 HK$0.0700 HK$0.0900 63
P/S Multiple HK$0.0400 HK$0.0600 HK$0.0700 58
P/B Multiple HK$0.0400 HK$0.0600 HK$0.0700 55
EV/EBIT HK$0.2200 HK$0.2600 HK$0.3000 66
EV/EBITDA HK$0.6100 HK$0.7800 HK$0.9500 67
EV/Revenue HK$0.1900 HK$0.2200 HK$0.2600 54
Asset-Based
NCAV (Graham) HK$0.1000 HK$0.1300 HK$0.1900 54
Growth DCF
Growth DCF HK$0.5600 HK$0.6700 HK$0.8000 80
Rev-Margin DCF HK$0.3500 HK$0.4100 HK$0.4700 74
Economic Profit
Residual Income HK$0.1200 HK$0.1100 HK$0.0800 76
ROIC Compounder HK$0.1400 HK$0.1500 HK$0.1500 72
Growth Earnings
Growth-Adj P/E HK$0.0400 HK$0.0600 HK$0.0700 68

Widest divergence: DCF Models (HK$0.4800) versus Earnings-Based (HK$0.0500). Highest evidence: FCF DCF (82).

Notify me when 2135 reaches fair value

Put 2135 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Free, no payment details. Unsubscribe anytime in one click.

Key figures & financial health

P/S ratio 0.36 TTM
EPS (TTM) HK$−0.0100
Net margin 1.0% FY2025
Return on equity −2.3% TTM
Return on assets (EBIT) −5.2% avg 5y
Operating margin 12.2% TTM
More key figures
Growth
Revenue (TTM) HK$189M TTM
Revenue growth (YoY) +28.0% 3y avg +3.9%
EPS growth (YoY) +88.7%
Balance sheet & cash flow
Free cash flow HK$32.0M FY2025
Net debt HK$1.4M FY2025 · ≈ 0.0 yrs of FCF

Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 53/100

Of which business quality 55 · Market factors (momentum, volatility) 29

Profitability 34
Margins and returns on capital today
Quality Growth 68
Are margins and returns improving?
Cashflow 85
Earnings quality: real cash, not paper profit
Fin. Strength 50
Balance sheet, leverage, solvency risk
Investment 100
Disciplined investing over empire-building
Low Volatility 50
Calm price path (market factor)
Momentum 20
Price trend over the last 3–12 months (market factor)
52W Momentum 20
Distance to the 52-week high (market factor)
Net Issuance 2
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.

About the company

Raily Aesthetic Medicine International Holdings Limited, an investment holding company, provides aesthetic medical services in the People's Republic of China. It operates through Aesthetic Medical Services, Consulting Services, and Aesthetic Medical Equipment Products segments.

Full company description

Raily Aesthetic Medicine International Holdings Limited, an investment holding company, provides aesthetic medical services in the People's Republic of China. It operates through Aesthetic Medical Services, Consulting Services, and Aesthetic Medical Equipment Products segments. The company provides aesthetic surgery services, including aesthetic surgery services comprising aesthetic surgical procedures performed on various parts of the face or body; minimally invasive aesthetic services, such as aesthetic injection procedures; aesthetic dermatology services that consists of various aesthetic energy-based procedures and photoelectric items; aesthetic dental services that include orthodontics, dental implant, and dental whitening; and aesthetic medical management consulting services. It also offers aesthetic medical equipment products comprising collagen injection products, surgical implants, and aesthetic medical skincare products. In addition, the company owns and operates a network of private for-profit aesthetic medical institutions; and trades in medical equipment. It serves individual retail clients and aesthetic medical institutions. Raily Aesthetic Medicine International Holdings Limited was founded in 2008 and is headquartered in Hangzhou, the People's Republic of China. The company operates as a subsidiary of Ruide Consultation Limited.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Raily Aesthetic Medicine Intl Hldg reported revenue of 185M CNY in FY2025 versus 188M CNY in FY2021, a compound −0.5%/yr. Reported net income was 1.8M CNY in FY2025.

Growth Quality 56/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Latest Revenue (FY 2025)
HK$185M
Latest YoY
−7.4%
Avg. revenue growth/yr (3Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+3.9%
Avg. revenue growth/yr (5Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+2.3%
Avg. revenue growth/yr (8Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+6.3%
Value creation/yr (5Y) ⓘEarnings growth per share (CAGR 5 years) plus dividend yield: value created per share and year.
−1.0% · in HKD
Earnings growth per share plus dividend yield: the value created per share and year.
Earnings growth per share−1.0%
Dividend yield0.0%
Operating margin (EBIT) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.6.1% (2020) → 2.7% (2025) · falling
Worst earnings drop783% (2022) (loss year, drop beyond 100%) · in HKD
Revenue −0.5%/yr
FY21 188M CNY
FY22 165M CNY
FY23 189M CNY
FY24 199M CNY
FY25 185M CNY
Net income
FY21 −17.7M CNY
FY22 −15.9M CNY
FY23 −32.5M CNY
FY24 −59.2M CNY
FY25 1.8M CNY

2135 screens 71% overvalued. Compare with HCA Healthcare, Inc →

Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
Share or link this analysis
𝕏 Post WhatsApp LinkedIn Reddit
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Raily Aesthetic Medicine Intl Hldg · Fair Value
HK$0.0680 −71%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Raily Aesthetic Medicine Intl Hldg Fair Value". https://www.fairvalue-calculator.com/stock/2135.HK

Peer Group

Medical Care Facilities · 257 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 53 · Below median
Fair Value upside −41% · Below median
Return on assets 1% · Below median
Net margin (TTM) 1% · Below median
Operating margin (TTM) 12% · Above median
Revenue growth 28% · Top 25%

Valuation Multiples vs Medical Care Facilities median · lower = cheaper

P/B 0.08× · Cheaper than 75% of peers
P/S (TTM) 0.05× · Cheaper than 75% of peers
P/FCF 0.3× · Cheaper than 75% of peers

Strength profile in five axes (Snowflake)

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE0 · sector 22
FUTURE100 · sector 26
PAST0 · sector 30
HEALTH100 · sector 90
DIVIDEND0 · sector 42

VALUE 0: the price sits above our fair-value range.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).

Stock Price Fair Value vs Fair Value
HCA Healthcare, Inc HCA $417.82 $547.67 +31%
Fresenius SE FRE €45.25 €32.15 −29%
Dr. Sulaiman Al Habib Medical Services Group 4013 241.00 SAR 112.37 SAR −53%
IHH Healthcare Berhad, an investment holding company, Q0F 2.67 SGD 1.44 SGD −46%
Tenet Healthcare Corporation THC $266.80 $330.25 +24%
DaVita Inc DVA $180.68 $186.49 +3%
Apollo Hospitals Enterprise Limited APOLLOHOSP ₹8,818 ₹2,955 −66%
Fresenius Medical Care AG FME €39.92 €71.28 +79%
Aier Eye Hospital Group 300015 ¥8.25 ¥7.67 −7%
Max Healthcare Institute Limited MAXHEALTH ₹1,005 ₹284.87 −72%

Compare Raily Aesthetic Medicine Intl Hldg with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screener Filter by region, size and sector Compare tool Two stocks side by side Extrinsic Value Calculator (Options) Splits an option premium into intrinsic and extrinsic (time) value. Peter Lynch Fair Value Formula & Calculator Apply Peter Lynch's fair value formula in seconds: fair P/E ≈ earnings growth (+ dividend) - free, with formula and example.

Frequently asked questions

Is Raily Aesthetic Medicine Intl Hldg (2135) overvalued or undervalued?
As of Aug 13, 2026, our model estimates a fair value of HK$0.0680 versus a price of HK$0.1160, about −41% upside (overvalued).
What is the fair value of 2135?
Our model-based fair value for Raily Aesthetic Medicine Intl Hldg is HK$0.0680 (as of Aug 13, 2026), built from audited fundamentals. The current price: HK$0.1160.
What is the quality score of 2135?
Raily Aesthetic Medicine Intl Hldg has a Quality Score of 53/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Raily Aesthetic Medicine Intl Hldg (2135)?
Our model-based price target is the fair value of HK$0.0680 (as of Aug 13, 2026) from 25 valuation models. Cautious scenario HK$0.0510, optimistic scenario HK$0.0850. It is a calculation from audited fundamentals, not an analyst target.
What is the Raily Aesthetic Medicine Intl Hldg stock forecast for 2026?
Our models put fair value at HK$0.0680, about −41% upside versus a price of HK$0.1160 (overvalued). Cautious scenario HK$0.0510, optimistic scenario HK$0.0850. The calculation is refreshed regularly with new filings.
What is the revenue of Raily Aesthetic Medicine Intl Hldg (2135)?
Raily Aesthetic Medicine Intl Hldg reported trailing-twelve-month revenue of about HK$189M (latest available figure, as of Aug 13, 2026).
What is the net profit margin of 2135?
The net profit margin of Raily Aesthetic Medicine Intl Hldg is about 1.0%, meaning it keeps roughly 1.0% of revenue as net income. Based on the latest reported figures.
Free · no account needed

Watch Raily Aesthetic Medicine Intl Hldg in the live analysis

One click puts Raily Aesthetic Medicine Intl Hldg on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.